SCHEMBL2735591

SCHEMBL2735591

CC(=O)NCCCCC(NC(C)=O)C(=O)O

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FOLH1 Q04609 6/20 0.71
SMN1; SMN2 Q16637 2/20 0.58
ALB P02768 2/20 0.54
KDM4E B2RXH2 2/20 0.54
MAPK1 P28482 1/20 0.54
HIF1A Q16665 1/20 0.54
SIRT5 Q9NXA8 2/20 0.52
SIRT6 Q8N6T7 1/20 0.51
SIRT1 Q96EB6 1/20 0.51
MAPT P10636 1/20 0.50
THRB P10828 1/20 0.50
ALOX15 P16050 1/20 0.50
NFKB1 P19838 1/20 0.50
PTGS2 P35354 1/20 0.50
THPO P40225 1/20 0.50
RECQL P46063 1/20 0.50
BLM P54132 1/20 0.50
GNPAT O15228 1/20 0.49
ADRA1A P35348 1/20 0.48
ALDH1A1 P00352 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1200060 1.00 FOLH1 (0.71) FOLH1SMN1; SMN2ALBKDM4EMAPK1
SCHEMBL16393150 1.00 FOLH1 (0.71) FOLH1SMN1; SMN2ALBKDM4EMAPK1
Bisorcic SCHEMBL2109666 0.94 FOLH1 (0.64) FOLH1SMN1; SMN2ALBKDM4EMAPK1
Bisorcic SCHEMBL2109664 0.94 FOLH1 (0.64) FOLH1SMN1; SMN2ALBKDM4EMAPK1
Bisorcic SCHEMBL16238411 0.94 FOLH1 (0.64) FOLH1SMN1; SMN2ALBKDM4EMAPK1
SCHEMBL25550095 0.93 FOLH1 (0.64) FOLH1SMN1; SMN2ALBKDM4EMAPK1
SCHEMBL14942518 0.93 FOLH1 (0.64) FOLH1SMN1; SMN2ALBKDM4EMAPK1
SCHEMBL13901989 0.91 FOLH1 (0.61) FOLH1SMN1; SMN2ALBKDM4EMAPK1
SCHEMBL23451113 0.89 FOLH1 (0.63) FOLH1SMN1; SMN2ALBKDM4EMAPK1
SCHEMBL17190067 0.88 FOLH1 (0.66) FOLH1SMN1; SMN2ALBKDM4EMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220002230-A1 COMPOUND CONTAINING DIPHENYLMETHANE STRUCTURE AND USE THEREOF GUANGZHOU CONGEN PHARMATEC CO., LTD. (CN) 2022-01-06 US disclosed
US-11014953-B2 Trigger-activatable metabolic sugar precursors for cancer-selective labeling and targeting THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2021-05-25 US disclosed
EP-3712181-A1 HYALURONIC ACID DERIVATIVE MODIFIED WITH POLY(ETHYLENE GLYCOL) Chugai Seiyaku Kabushiki Kaisha (JP) 2020-09-23 EP disclosed
WO-2017062800-A1 TRIGGER-ACTIVATABLE METABOLIC SUGAR PRECURSORS FOR CANCER-SELECTIVE LABELING AND TARGETING THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2017-04-13 WO disclosed
US-9558862-B2 Conductive polymer composition, coated article having antistatic film formed from the composition, and patterning process using the composition SHIN-ETSU POLYMER CO., LTD. (JP) 2017-01-31 US disclosed
US-9558862-B2 Conductive polymer composition, coated article having antistatic film formed from the composition, and patterning process using the composition SHIN-ETSU POLYMER CO., LTD. (JP) 2017-01-31 US disclosed
EP-2868698-B1 CONDUCTIVE POLYMER COMPOSITION, COATED ARTICLE WHICH IS PROVIDED WITH ANTISTATIC FILM OBTAINED FROM CONDUCTIVE POLYMER COMPOSITION, AND PATTERN FORMING METHOD USING CONDUCTIVE POLYMER COMPOSITION SHINETSU POLYMER CO (JP) 2016-12-07 EP disclosed
US-9132111-B2 Topical antimicrobial compositions LU KEWANG (US) 2015-09-15 US disclosed
US-20150140492-A1 CONDUCTIVE POLYMER COMPOSITION, COATED ARTICLE HAVING ANTISTATIC FILM FORMED FROM THE COMPOSITION, AND PATTERNING PROCESS USING THE COMPOSITION SHIN-ETSU POLYMER CO., LTD. (JP) 2015-05-21 US disclosed
US-20150140492-A1 CONDUCTIVE POLYMER COMPOSITION, COATED ARTICLE HAVING ANTISTATIC FILM FORMED FROM THE COMPOSITION, AND PATTERNING PROCESS USING THE COMPOSITION SHIN-ETSU POLYMER CO., LTD. (JP) 2015-05-21 US disclosed
US-20090054590-A1 Multi-armed, monofunctional, and hydrolytically stable derivatives of poly (ethylene glycol) and related polymers for modification of surfaces and molecules NEKTAR THERAPEUTICS AL, CORPORATION (US) 2009-02-26 US disclosed
EP-0015771-B1 N-(6-((ACYLAMINOACYLAMINO OR AMINOACYLAMINO)PHENYL)-1,2-DIHYDRO-2-OXONICOTINYL) CEPHALOSPORIN COMPOUNDS, PROCESSES FOR THEIR PRODUCTION, AND COMPOSITIONS CONTAINING THE SAME WARNER-LAMBERT COMPANY (US) 1984-06-06 EP disclosed
EP-0015773-B1 N-(6-((ACYLAMINOACYLAMINO OR AMINOACYLAMINO)PHENYL) 1,2-DIHYDRO-2-OXONICOTINYL)PENICILLIN COMPOUNDS, PROCESSES FOR THEIR PRODUCTION AND COMPOSITIONS CONTAINING THEM WARNER-LAMBERT COMPANY (US) 1983-07-20 EP disclosed
US-4311699-A Aminoacid derivatives of cephalosporin compounds HASKELL THEODORE H 1982-01-19 US disclosed
US-4311698-A Aminoacid derivatives of cephalosporin compounds HASKELL THEODORE H 1982-01-19 US disclosed
US-4278681-A N-/6-//ACYLAMINOACYLAMINO OR AMINOACYLAMINO/PHENYL/-1,2-DIHYDRO-2-OXONICOTINYL/PENICILLINS WARNER-LAMBERT CO. (US) 1981-07-14 US disclosed
US-4267180-A PENICILLINS AND DERIVATIVES WARNER-LAMBERT COMPANY (US) 1981-05-12 US disclosed
EP-0015773-A2 N-(6-((acylaminoacylamino or aminoacylamino)phenyl) 1,2-dihydro-2-oxonicotinyl)penicillin compounds, processes for their production and compositions containing them WARNER-LAMBERT COMPANY (US) 1980-09-17 EP disclosed
EP-0015771-A1 N-(6-((acylaminoacylamino or aminoacylamino)phenyl)-1,2-dihydro-2-oxonicotinyl) cephalosporin compounds, processes for their production, and compositions containing the same WARNER-LAMBERT COMPANY (US) 1980-09-17 EP disclosed
EP-0015772-A1 N-(2-((acylaminoacylamino or aminoacylamino)phenyl)-4-hydroxy-5-pyrimidinylcarbonyl)cephalosporin compounds, processes for their production, and compositions containing the same WARNER-LAMBERT COMPANY (US) 1980-09-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11014953-B2 Trigger-activatable metabolic sugar precursors for cancer-selective labeling and targeting GPI, SLC2A1, SLC2A4 FOLH1 240/4885SMN1; SMN2 3380/4885ALB 1569/4885
US-20220002230-A1 COMPOUND CONTAINING DIPHENYLMETHANE STRUCTURE AND USE THEREOF PEPD, VIP, DNPEP FOLH1 146/4885SMN1; SMN2 2430/4885ALB 632/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.